Scientists identify protein Miro1 as driver of Type 2 diabetes
Researchers at Pennington Biomedical Research Center published findings on November 8, 2026, linking the protein Miro1 to insulin resistance in people with Type 2 diabetes.
Protein buildup blocks muscle response
Scientists discovered that high levels of the protein Miro1 accumulate in skeletal muscles of patients with Type 2 diabetes. This buildup interferes with how the body responds to insulin, making blood sugar regulation difficult. Preclinical experiments showed that removing Miro1 restored normal muscle function and improved insulin sensitivity in models. The study traced this protein from laboratory cells through preclinical models to actual human patients.
Exercise lowers harmful protein levels
A randomized controlled trial compared aerobic exercise against standard medical care for participants with obesity and Type 2 diabetes. People in the exercise group experienced a decline in Miro1 levels within their muscles over time. These reductions occurred alongside measurable improvements in insulin sensitivity and the muscles capacity to produce energy. The findings suggest that physical activity helps lower this specific protein to aid disease management.
New target for future treatments
The research team published these results in the journal Nature Communications on November 8, 2026. They believe treatments designed to target Miro1 could provide additional benefits alongside current physical activity recommendations. Insulin resistance in muscle remains a central feature of Type 2 diabetes that has frustrated researchers for years. Identifying Miro1 offers a promising new pathway for understanding the biological processes behind this condition.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.